DGAP-News

Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis - Seite 3

*****

Abivax will host a virtual KOL event as webcast on Tuesday, April 20, 2021 at 1:30 pm CEST (7:30 am EDT), ahead of the data read-out of its ABX464 phase 2b clinical study in UC. Prof. Bruce Sands, M.D., M.S., Chief of the Division of Gastroenterology at the Mount Sinai School of Medicine in New York City, NY, will provide expert information on existing and future treatment options for UC, including current unmet medical needs. In addition, Abivax will provide an update on the safety and efficacy of ABX464 as it applies to UC.

To participate in the webcast, please follow the weblink: https://media.rampard.com/20210420/

*****

About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax Communications Regina Jehle [e-mail] [phone]	Investors LifeSci Advisors Chris Maggos [e-mail] [phone]	Press Relations & Investors Europe MC Services AG Anne Hennecke [e-mail] [phone]
Public Relations France Actifin Ghislaine Gasparetto [e-mail] [phone]	Public Relations France DGM Conseil Thomas Roborel de Climens [e-mail] [phone]	Public Relations USA